ARS Pharmaceuticals, Inc.SPRYNASDAQ
Loading
Year-over-year research & development expense growth
3Y CAGR
+6.2%/yr
Quarterly compound
Percentile
P78
Within normal range
vs 3Y Ago
1.2x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 25.15% |
| Q3 2025 | -31.82% |
| Q2 2025 | 36.69% |
| Q1 2025 | -2.48% |
| Q4 2024 | -31.56% |
| Q3 2024 | -35.86% |
| Q2 2024 | 31.75% |
| Q1 2024 | 53.76% |
| Q4 2023 | 13.39% |
| Q3 2023 | -58.92% |
| Q2 2023 | 11.54% |
| Q1 2023 | 39.11% |
| Q4 2022 | 20.99% |
| Q3 2022 | -10.51% |
| Q2 2022 | -19.79% |
| Q1 2022 | 38.55% |
| Q4 2021 | -23.58% |
| Q3 2021 | -8.84% |
| Q2 2021 | 0.00% |
| Q1 2021 | -35.03% |
| Q4 2020 | 0.00% |
| Q2 2020 | 16.68% |
| Q1 2020 | -31.85% |
| Q4 2019 | 0.00% |